2160.HK MicroPort CardioFlow HK$3.89 on heavy volume 25 Feb 2026: overbought
The 2160.HK stock surged intraday to HK$3.89, trading 1,679,000 shares on the Hong Kong Stock Exchange. Volume ran at about 1.68M versus an average of 6.92M, driving a HK$3.05 jump and a reported +363.10% change from the prior close of HK$0.84. This high-volume move is the day’s defining market event in Hong Kong healthcare. Traders should note the stock’s stretched technicals and mixed fundamentals while we track catalysts and short-term trade rules.
2160.HK stock: intraday price and volume snapshot
Intraday action shows a day low HK$3.75 and day high HK$4.20 on 25 Feb 2026. Market cap is about HK$395,407,610 with 482,204,403 shares outstanding. The stock opened at HK$4.00 after a prior close of HK$0.84, indicating a corporate event or trade re-rating that lifted price and volume. We link recent split calendars as a potential catalyst. See the split calendar at Investing.com.
2160.HK stock fundamentals: cash, ratios and growth
MicroPort CardioFlow (2160.HK) lists EPS at -0.02, making a standard PE ratio not meaningful for valuation. The stock shows a price-to-book of 0.15 and cash per share HK$2.83, supporting a strong liquidity profile. Revenue per share is HK$0.79 and free cash flow per share is negative HK$-0.39. Current ratio sits at 6.94, and debt to equity is 0.13, which cushions short-term claims but highlights ongoing investment spending.
2160.HK stock technicals: overbought signals and trend strength
Technical indicators are extreme. RSI is 94.74 (overbought) and ADX is 42.48, signaling a strong directional move. MACD histogram is 0.22 positive. Bollinger middle band sits near HK$1.00, showing the recent spike is well above moving averages. Traders should treat this as a high-volatility setup. Consider intraday stops because momentum can reverse quickly from these levels.
Meyka AI rates 2160.HK with a score out of 100 and model forecast
Meyka AI rates 2160.HK with a score out of 100: Score 68, Grade B, Suggestion: HOLD. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus. Meyka AI’s forecast model projects yearly HK$1.16, a -70.12% implied move from the current HK$3.89. Forecasts are model-based projections and not guarantees. Use the model projection alongside company filings and regulatory updates when evaluating position size.
2160.HK stock risks and catalysts
Key catalysts include regulatory approvals, procedure adoption for the Vitaflow valve, and clinical data updates. Major risks include reimbursement delays, competitive device launches, and thin trading that magnifies moves. R&D spending accounts for about 33.12% of revenue, which is a growth driver but also a cash drain if procedure uptake slows. Monitor upcoming earnings announcement scheduled for 31 Mar 2026.
Trading strategy for this high-volume mover
For intraday traders, use tight risk controls. Consider limit entries near support and place stops below HK$3.50 if long. Short-term targets: day resistance HK$4.20 and intraday exit if RSI crosses below 85. For position traders, set a 12-month base case price target HK$1.15, bear HK$0.80, and bull HK$2.50 based on adoption scenarios. Always size positions for this stock’s volatility.
Final Thoughts
2160.HK stock is the session’s high-volume mover in Hong Kong healthcare. The intraday spike to HK$3.89 on 1,679,000 shares highlights speculative flow and possible corporate actions. Fundamentals show strong cash per share HK$2.83 and a low price-to-book 0.15, but EPS is negative, making headline ratios unreliable. Technicals point to overbought conditions with RSI 94.74 and ADX 42.48, so momentum can reverse quickly. Meyka AI’s forecast model projects HK$1.16 for the year, implying -70.12% from the current price; forecasts are model-based projections and not guarantees. Our trading framework: treat intraday moves as short-term trades, use tight stops, and weigh longer-term positions against company milestones and actual volume normalization. For investors, a base 12-month price target HK$1.15 reflects mean reversion; outperforming clinical or reimbursement news would be required to justify higher targets.
FAQs
What caused the intraday move in 2160.HK stock?
Intraday volume spiked to 1,679,000 shares and price jumped to HK$3.89. The move aligns with market re-rating and calendar listings for corporate actions. Traders should check company announcements and the split calendar at Investing.com.
What is Meyka AI’s forecast for 2160.HK stock?
Meyka AI’s forecast model projects a yearly price of HK$1.16, implying -70.12% from the intraday HK$3.89. Forecasts are model-based projections and not guarantees. Use them with company news and filings.
Is 2160.HK stock a buy after the spike?
Given extreme technicals and mixed fundamentals, treat the spike as high-risk. Meyka AI grades 2160.HK B (HOLD). Short-term traders may scalp; longer-term investors should wait for clearer clinical or revenue signals.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.